Positive results with lenvatinib for the treatment of advanced medullary thyroid cancer in a phase II trial

被引：0
|
作者：
机构：
来源：
Nature Reviews Endocrinology | 2015年 / 11卷 / 11期
关键词：
D O I：
10.1038/nrendo.2015.157
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：632 / 632
相关论文
共 50 条
  • [1] A phase II trial of the multitargeted kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer (MTC).
    Schlumberger, Martin
    Jarzab, Barbara
    Cabanillas, Maria E.
    Robinson, Bruce
    Pacini, Furio
    Ball, Douglas Wilmot
    McCaffrey, Judith C.
    Newbold, Kate
    Allison, Roger
    Martins, Renato
    Licitra, Lisa F.
    Shah, Manisha H.
    Bodenner, Donald
    Elisei, Rossella
    Burmeister, Lynn A.
    Funahashi, Yasuhiro
    Sellecchia, Rita
    Andresen, Corina
    O'Brien, James P.
    Sherman, Steven I.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer
    Schlumberger, Martin
    Jarzab, Barbara
    Cabanillas, Maria E.
    Robinson, Bruce
    Pacini, Furio
    Ball, Douglas W.
    McCaffrey, Judith
    Newbold, Kate
    Allison, Roger
    Martins, Renato G.
    Licitra, Lisa F.
    Shah, Manisha H.
    Bodenner, Donald
    Elisei, Rossella
    Burmeister, Lynn
    Funahashi, Yasuhiro
    Ren, Min
    O'Brien, James P.
    Sherman, Steven I.
    CLINICAL CANCER RESEARCH, 2016, 22 (01) : 44 - 53
  • [3] A PHASE II TRIAL OF THE MULTI-TARGETED KINASE INHIBITOR LENVATINIB (E7080) IN ADVANCED MEDULLARY THYROID CANCER (MTC)
    Schlumberger, M.
    Jarzab, B.
    Cabanillas, M. E.
    Robinson, B.
    Furio, P.
    Ball, D. W.
    McCaffrey, J. C.
    Newbold, K.
    Allison, R.
    Martins, R. G.
    Licitra, L.
    Shah, M. H.
    Bodenner, D. L.
    Elisei, R.
    Burmeister, L. A.
    Funahashi, Y.
    Sellecchia, R.
    Andresen, C.
    O'Brien, J. P.
    Sherman, S.
    ANNALS OF ONCOLOGY, 2012, 23 : 35 - 36
  • [4] Phase II study of lenvatinib in patients with differentiated, medullary, and anaplastic thyroid cancer: Final analysis results.
    Takahashi, Shunji
    Kiyota, Naomi
    Yamazaki, Tomoko
    Chayahara, Naoko
    Nakano, Kenji
    Inagaki, Lina
    Toda, Kazuhisa
    Enokida, Tomohiro
    Minami, Hironobu
    Imamura, Yoshinori
    Sasaki, Tatsuya
    Suzuki, Takuya
    Fujino, Katsuki
    Dutcus, Corina
    Tahara, Makoto
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer
    Matrone, A.
    Prete, A.
    Nervo, A.
    Ragni, A.
    Agate, L.
    Molinaro, E.
    Giani, C.
    Valerio, L.
    Minaldi, E.
    Piovesan, A.
    Elisei, R.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2021, 44 (10) : 2139 - 2151
  • [6] Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer
    A. Matrone
    A. Prete
    A. Nervo
    A. Ragni
    L. Agate
    E. Molinaro
    C. Giani
    L. Valerio
    E. Minaldi
    A. Piovesan
    R. Elisei
    Journal of Endocrinological Investigation, 2021, 44 : 2139 - 2151
  • [7] Phase I/II trial of vandetanib and bortezomib in adults with locally advanced or metastatic medullary thyroid cancer: Phase I results.
    Gramza, A. W.
    Wells, S. A.
    Balasubramaniam, S.
    Fojo, A. T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] Phase II trial of sunitinib in medullary thyroid cancer (MTC)
    De Souza, J. A.
    Busaidy, N.
    Zimrin, A.
    Seiwert, T. Y.
    Villaflor, V. M.
    Poluru, K. B.
    Reddy, P. L.
    Nam, J.
    Vokes, E. E.
    Cohen, E. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Correction to: Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer
    A. Matrone
    A. Prete
    A. Nervo
    A. Ragni
    L. Agate
    E. Molinaro
    C. Giani
    L. Valerio
    E. Minaldi
    A. Piovesan
    R. Elisei
    Journal of Endocrinological Investigation, 2021, 44 : 2859 - 2859
  • [10] Treatment of advanced medullary thyroid cancer
    Smit J.
    Thyroid Research, 6 (Suppl 1)
12345